Skip to main content
. 2021 Oct 29;22(21):11781. doi: 10.3390/ijms222111781

Figure 2.

Figure 2

CAR-T cell therapy approach against colorectal cancer. Firstly, human T cells are obtained, selected and activated in vitro. Genetic modification is performed to induce CAR expression in the T cell, and the obtained CAR-T cells are expanded and formulated to manufacture the CAR-T cell product with the corresponding quality controls. The CAR-T cell product is administered to the patient, where it is expected to eliminate the tumour cells by targeting the different CRC antigens. Created with Biorender.com.